Health1 min read

STAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NAC

By · Via STAT Health · Published by Everything Blog

In short

The Food and Drug Administration is formally proposing a new regulatory classification specifically for N-acetyl-L-cysteine, commonly known as NAC. The compound has historically faced regulatory friction due to its initial authorization as an active pharmaceutical ingredient alongside widespread consumer sales. Establishing an explicit administrative pathway provides defined compliance standards for industry stakeholders navigating federal dietary rules.

Key points

  • Federal health officials are establishing a formal regulatory classification specifically…: Federal health officials are establishing a formal regulatory classification specifically tailored for N-acetyl-L-cysteine.
  • The agency's proposal seeks to clearly define market rules for the compound under federal…: The agency's proposal seeks to clearly define market rules for the compound under federal oversight.
  • Product manufacturers will gain administrative clarity as the Food and Drug Administratio…: Product manufacturers will gain administrative clarity as the Food and Drug Administration refines its regulatory stance.

Sources checked by our analysis pipeline: 1

WASHINGTON – The Food and Drug Administration is proposing a new classification for a product that’s existed in a legal grey area for years, a win for proponents of dietary supplements, including members of the MAHA movement.

The proposed rule would classify N-acetyl-L-cysteine, known as NAC and already widely sold over-the-counter, as the agency’s first “Dietary Ingredient Not Excluded from the Dietary Supplement Definition” — in essence, not not a supplement.

The need for the legal backbending stems from the fact that the FDA previously approved NAC as a drug, and FDA regulations prohibit the agency from including approved drugs in the dietary supplement category. In 1963, the agency approved NAC to break up mucus in certain lung conditions, and in 1974 to treat acetaminophen overdose.

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Health